Skip to main content
SpringerLink
Log in
Book cover

Molecular Aspects of Anticancer Drug-DNA Interactions pp 169–212Cite as

New Platinum Drugs

  • Chapter

Part of the book series: Topics in Molecular and Structural Biology ((TMSB))

Abstract

Following the well-documented serendipitous discovery of the antitumour properties of cis-diamminedichloro platinum(II) (cisplatin) in the mid 1960s (see Rosenberg, 1985, for a review), the drug was introduced into clinical practice in 1971. While the introduction of cisplatin has undoubtedly made a dramatic impact on the response rates (and long-term survival) obtained for patients presenting with some tumour types (notably testicular teratoma and ovarian carcinoma), much effort has been, and continues to be, expended towards the discovery and development of additional platinum-based anticancer drugs. Platinum drug development has proceeded in two broad directions concomitant with the two main limitations of cisplatin itself: namely its severe side-effects (especially on the kidneys, gastrointestinal tract and peripheral nerves) and its poor activity against some common tumours (e.g. colorectal and non-small-cell lung cancers) combined with its inability to confer lasting remissions in responding tumour types (especially ovarian) due to the emergence of drug resistance.

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aamdal, S., Piccart, M., Wanders, J., Rastogi, R. B., Schwartsman, G., Franklin, H. R. and Kaye, S. B. (1991). Phase II study of zeniplatin (CL286,558) [2,2bis(aminomethyl)-1,3-propanediol-N,N’] [1, 1-cyclobutanedicarboxylato(2-)O,O’]platinum(II) in patients with advanced melanoma. Proceedings of the Sixth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, p. 167

    Google Scholar 

  • Advanced Ovarian Cancer Trialists Group (1991). Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. Br. Med. J., 303, 884–893

    Article  Google Scholar 

  • Alvarez, M., Rixe, O., Reed, E. and Fojo, A. T. (1992). Characterization of protein changes in cisplatin (CP) resistant A2780 human ovarian carcinoma and KB cell lines. Proc. Am. Assoc. Cancer Res., 33, A3224

    Google Scholar 

  • Anderson, W. K., Quagliato, D. A., Haugwitz, R. D., Narayanan, V. L. and Wolpert-DeFilippes, M. K. (1986). Synthesis, physical properties and antitumor activity of tetraplatin and related tetrachloroplatinum (IV) stereoisomers of 1,2-diaminocyclohexane. Cancer Treat. Rep., 70, 997–1002

    PubMed  CAS  Google Scholar 

  • Andrews, P. A. and Albright, K. D. (1992). Mitochondrial defects in cisdiamminedichloro platinum(II)-resistant human ovarian carcinoma cells. Cancer Res., 52, 1895–1901

    PubMed  CAS  Google Scholar 

  • Andrews, P. A. and Howell, S. B. (1990). Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2, 35–43

    PubMed  CAS  Google Scholar 

  • Andrews, P. A., Jones, J. A., Varki, N. M. and Howell, S. B. (1990). Rapid emergence of acquired cis-diamminedichloroplatinum (II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun., 2, 93–100

    PubMed  CAS  Google Scholar 

  • Andrews, P. A., Mann, S. C., Huynh, H. H. and Albright, K. D. (1991). Role of the Na+, K+-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum (II) in human ovarian carcinoma cells. Cancer Res., 51, 3677–3681

    PubMed  CAS  Google Scholar 

  • Andrews, P. A., Murphy, M. P. and Howell, S. B. (1987). Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Che-mother. Pharmacol., 19, 149–154

    CAS  Google Scholar 

  • Andrews, P. A., Murphy, M. P. and Howell, S. B. (1989). Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells. Eur. J. Cancer Clin. Oncol., 25, 619–625

    Article  PubMed  CAS  Google Scholar 

  • Andrews, P. A., Velury, S., Mann, S. C. and Howell, S. B. (1988). cisdiamminedichloro platinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res., 48, 68–73

    PubMed  CAS  Google Scholar 

  • Ariyoshi, Y. and Ota, K., (1989). Preclinical and clinical evaluation of toxicities and antitumour activities of cisplatin analogues. Jpn J. Cancer Chemother., 16, 1379–1385

    CAS  Google Scholar 

  • Ariyoshi, Y., Ota, K., Wakui, A., Majima, H., Niitani, H., Ogawa, M., Inuyama, Y., Yoshida, O., Taguchi, T., Kimura, I. and Kato, T. (1988). Phase I study of [glycolato-O,O’] diammine platinum (II) (254-S). Proc. Am. Soc. Clin. Oncol., 7, A222.

    Google Scholar 

  • Bakka, A., Endresen, L., Johnsen, A. B. S., Edminson, P. D. and Rugstad, H. E. (1981). Resistance against cis-diamminedichloro platinum in cultured cells with a high content of metallothionein. Toxicol. Appl. Pharmacol., 61, 215–226

    Article  PubMed  CAS  Google Scholar 

  • Basu, A., Kozikowski, A. P., Sato, K. and Lazo, J. S. (1991). Cellular sensitization to cis-diamminedichloro platinum (II) by novel analogues of the protein kinase C activator lyngbyatoxin A. Cancer Res., 51, 2511–2514

    PubMed  CAS  Google Scholar 

  • Basu, A. and Lazo, J. S. (1991). Suppression of dexamethasone-induced metallothionein expression and cis-diamminedichloro platinum (II) resistance by v-mos. Cancer Res., 51, 893–896

    PubMed  CAS  Google Scholar 

  • Basu, A. and Lazo, J. S. (1992). Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum (II) by bryostatin 1. Cancer Res., 52, 3119–3124

    PubMed  CAS  Google Scholar 

  • Basu, A., Teicher, B. A. and Lazo, J. S. (1990). Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloro platinum (II). J. Biol. Chem., 265, 8451–8457

    PubMed  CAS  Google Scholar 

  • Bedford, P., Fichtinger-Schepman, M. J., Shellard, S. A., Walker, M. C., Masters, J. R. W. and Hill, B. T. (1988). Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res., 48, 3019–3024

    PubMed  CAS  Google Scholar 

  • Behrens, B. C., Hamilton, T. C., Masuda, H., Grotzinger, K. R., Whang-Peng, J., Louie, K. G., Knutsen, T., McKoy, W. M., Young, R. C. and Ozols, R. F. (1987). Characterization of a cis-diamminedichloroplatinum (II)-resistant human ovarian carcinoma cell line and its use in evaluation of platinum analogs. Cancer Res., 47, 414–418

    PubMed  CAS  Google Scholar 

  • Bernal, S. D., Speak, J. A., Boeheim, K., Dreyfuss, A. I., Wright, J. E., Teicher, B. A., Rosowsky, A., Tsao, S. W. and Wong, Y. C. (1990). Reduced membrane protein associated with resistance of human squamous carcinoma cells to methotrexate and cis-platinum. Mol. Cell. Biochem., 95, 61–70

    Article  PubMed  CAS  Google Scholar 

  • Bitha, P., Carvajal, S. G., Citarella, R. V., Delos Santos, E. F., Durr, F. E., Hlavka, J. J., Lang, S. A., Lindsay, H. L., Thomas, J. P., Wallace, R. E. and Lin, Y. (1989). Water-soluble third generation antitumor platinum complexes, [2,2-bis(aminomethyl)-1,3-propanediol-N,N’][1,1-cyclobutanedicarboxylato (2-)O,O’]platinum(II) and [1,1-cyclobutanedicarboxylato (2-)-O,O’][tetrahydro4H-pyran-4,4-dimethanamine-N,N’]platinum(II). J. Med. Chem., 32, 2015–2020

    Article  PubMed  CAS  Google Scholar 

  • Boughattas, N. A., Levi, F., Fournier, C., Lemaigre, G., Roulon, A., Hecquet, B., Mathé, G. and Reinberg, A. (1989). Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum (II) in mice. Cancer Res., 49, 3362–3368

    PubMed  CAS  Google Scholar 

  • Bungo, M., Fujiwara, Y., Kasahara, K., Nakagawa, K., Ohe, Y., Sasaki, Y., Irino, S. and Saijo, N. (1990). Decreased accumulation as a mechanism of resistance to cis-diamminedichloro platinum (II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Res., 50, 2549–2553

    PubMed  CAS  Google Scholar 

  • Bunn, P., Canetta, R., Ozols, R. and Rozencweig, M. (Eds) (1990). Carboplatin; Current Perspectives and Future Directions. W. B. Saunders, Philadelphia

    Google Scholar 

  • Burchenal, J. H., Kalaher, K., Dew, K. and Lokys, L. (1979). Rationale for development of platinum analogs. Cancer Treat. Rep., 63, 1493–1498

    PubMed  CAS  Google Scholar 

  • Carfagna, P. F., Poma, A., Wyrick, S. D., Holbrook, D. J. and Chaney, S. G. (1991). Comparisons of tetrachloro(D,L-trans)1,2-diaminocyclohexaneplatinum(IV) biotransformations in the plasma of Fisher 344 rats at therapeutic and toxic doses. Cancer Chemother. Pharmacol., 27, 335–341

    Article  PubMed  CAS  Google Scholar 

  • Canetta, R., Rozencweig, M., Wittes, R. E. and Schacter, L. P. (1990). Platinum coordination complexes in cancer chemotherapy: an historical perspective. In Cancer Chemotherapy: Challenges for the Future, Vol. 5. Excerpta Medica, Tokyo, pp. 318–323

    Google Scholar 

  • Caussanell, J. P., Levi, F., Brienza, S., Misset, J. L., Itzhaki, M., Adam, R., Milano, G., Hecquet, B. and Mathé, G. (1990). Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J. Natl Cancer Inst., 82, 1046–1050

    Article  Google Scholar 

  • Ceulemans, F., Duprez, P., Vindevogel, A., Tueni, E., Piccart, M., Kerger, J., Rastogi, R. and de Halleux, F. (1991). Enloplatin (CL287,110): Phase I study in patients with advanced solid tumours. Proceedings of the Sixth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, p. 168

    Google Scholar 

  • Chao, C. C.-K., Lee, Y. L., Cheng, P.-W. and Lin-Chao, S. (1991). Enhanced host cell reactivation of damaged plasmid DNA in HeLa cells resistant to cis-diamminedichloroplatinum (II). Cancer Res., 51, 601–605

    PubMed  CAS  Google Scholar 

  • Christen, R. C., Horn, D. K., Porter, D. C., Andrews, P. A., MacLeod, C. L., Hafstrom, L. and Howell, S. B. (1990). Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J. Clin. Invest., 86, 1632–1640

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Christian, M. C., Kohn, E., Sarosy, G., Link, C., Davis, P., Adamo, D., Weiss, R. B., Brewster, L., Lombardo, F. and Reed, E. (1992). Phase I and pharmacologic study of ormaplatin (OP)/tetraplatin. Proc. Am. Soc. Clin. Oncol., 11, abs. 291

    Google Scholar 

  • Connors, T. A., Jones, M., Ross, W. C. J., Braddock, P. D., Khokhar, A. R. and Tobe, M. L. (1972). New platinum complexes with anti-tumour activity. Chem.biol. Interact., 5, 415–424

    Article  PubMed  CAS  Google Scholar 

  • Dabholkar, M., Bostick-Bruton, F. and Reed, E. (1992). ERCC1 and ERCC2 expression in fresh human tumor tissues. Proc. Am. Assoc. Cancer Res., 33, A1417

    Google Scholar 

  • De Graeff, A., Slebos, R. J. C. and Rodenhuis, S. (1988). Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Che-mother. Pharmacol., 22, 325–332

    Article  Google Scholar 

  • Dempke, W. C. M., Shellard, S. A., Fichtinger-Schepman, A. M. J. and Hill, B. T. (1991). Lack of significant modulation of the formation and removal of platinum—DNA adducts by aphidicolin glycinate in two logarithmically-growing ovarian tumour cell lines in vitro. Carcinogenesis, 12, 525–528

    Article  PubMed  CAS  Google Scholar 

  • Dodion, P. F., de Valeriola, D., Crepeigne, N., Kantrowitz, J. D., Piccart, M., Wery, F., Kerger, J., Egorin, M. J., Forrest, A., Bachur, N. R., Alaerts, P., Carver, A., Rastogi, R., Hammershaimb, L. and Saletan, S. (1991). Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex. Ann. Oncol., 2, 589–596

    PubMed  CAS  Google Scholar 

  • Dougherty, W. J., Tiner, J. D., Tham, P. and Irwin, M. (1991). Preclinical toxicology of enloplatin. Proceedings of the Sixth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, p. 297

    Google Scholar 

  • Eastman, A. (1990). Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells (Cold Spring Harbor), 2, 275–280

    CAS  Google Scholar 

  • Eastman, A. and Schulte, N. (1988). Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloro platinum (II). Biochemistry, 27, 4730–4734

    Article  PubMed  CAS  Google Scholar 

  • Eisenhauer, E., Swerton, K., Sturgeon, J., Fine, S., O’Reilly, S. and Canetta, R. (1990). Carboplatin therapy for recurrent ovarian carcinoma: National Cancer Institute of Canada experience and a review of the literature. In Bunn, P., Canetta, R., Ozols, R. and Rozencweig, M. (Eds), Carboplatin; Current Perspectives and Future Directions. W. B. Saunders, Philadelphia, pp. 133–140

    Google Scholar 

  • Enns, R. E. and Howell, S. B. (1991). Isolation of a gene associated with resistance to cisplatin. In Howell, S. B. (Ed.), Platinum and Other Metal Coordination Complexes in Cancer Chemotherapy. Plenum Press, New York, pp. 213–219

    Chapter  Google Scholar 

  • Extra, J. M., Espie, M., Calvo, F., Ferme, C., Mignot, L. and Marty, M. (1990). Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol., 25, 299–303

    Article  PubMed  CAS  Google Scholar 

  • Farrell, N., Kelland, L. R., Roberts, J. D. and Van Beusichem, M. (1992). Activation of the trans geometry in platinum antitumor complexes: A survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. Cancer Res., 52, 5065–5072

    PubMed  CAS  Google Scholar 

  • Farrell, N., Qu, Y., Feng, L. and Van Houten, B. (1990b). Comparison of chemical reactivity, cytotoxicity, interstrand cross-linking and DNA sequence specificity of bis(platinum) complexes containing monodentate or bidentate coordination spheres with their monomeric analogues. Biochemistry, 29, 9522–9531

    Article  PubMed  CAS  Google Scholar 

  • Farrell, N., Qu, Y. and Hacker, M. P. (1990a). Cytotoxicity and antitumor activity of bis(platinum) complexes. A novel class of platinum complexes active in cell lines resistant to both cisplatin and 1,2-diaminocyclohexane complexes. J. Med. Chem., 33, 2179–2184

    Article  PubMed  CAS  Google Scholar 

  • Fiebig, H. H., Berger, D. P., Mross, K., Queiber, W., Aulenbacher, P. and Hilgard, P. (1992). Lobaplat (D19466): Preclinical drug profile and results of the phase I study. Ann. Oncol., 3 (Suppl. 1), A338

    Google Scholar 

  • Fram, R. J., Woda, B. A., Wilson, J. M. and Robichaud, N. (1990). Characterization of acquired resistance to cis-diamminedichloro platinum (II) in BE human colon carcinoma cells. Cancer Res., 50, 72–77

    PubMed  CAS  Google Scholar 

  • Freise, J., Mueller, W. H., Magerstedt, P. and Schmoll, H. J. (1982). Pharmacokinetics of liposome-encapsulated cis-platin in rats. Arch. Int. Pharmacodyn. Ther., 258, 180–192

    PubMed  CAS  Google Scholar 

  • Fujiwara, Y., Sugimoto, Y., Kasahara, K., Bungo, M., Yamakido, Y., Tew, K. D. and Saijo, N. (1990). Determinants of drug response in a cisplatin-resistant human lung cancer cell line. Jpn J. Cancer Res., 81, 527–535

    Article  PubMed  CAS  Google Scholar 

  • Fukuda, M., Shinkai, T., Eguchi, K., Sasaki, Y., Tamura, T., Ohe-Y., Kojima, A., Oshita, F., Hara, K. and Saijo, N. (1990). Phase II study of (glycolate-O,O’) diammineplatinum(II), a novel platinum complex, in the treatment of non-smallcell lung cancer. Cancer Chemother. Pharmacol., 26, 393–396

    CAS  Google Scholar 

  • Fukuoka, M., Niitani, H., Hasegawa, K., Majima, H., Hino, M., Furue, H., Tsukagoshi, S., Fujita, H., Ohta, K., Furuse, K., Kimura, I. and Katoh, T. (1989). Phase I study of new platinum compound, NK121. Proc. Am. Soc. Clin. Oncol., 8, A240

    Google Scholar 

  • Galeano, A., Berger, M. R. and Keppler, B. K. (1992). Activity of two platinum-linked phosphonic acids against autochthonous rat colorectal cancer as well as in two human colon-cancer cell lines. Cancer Chemother. Pharmacol., 30, 131–138

    Article  PubMed  CAS  Google Scholar 

  • Giandomenico, C. M., Abrams, M. J., Murrer, B. A., Vollano, J. F., Harrap, K. R., Goddard, P. M., Kelland, L. R. and Morgan, S. E. (1991). Synthesis and reactions of a new class of orally active Pt (IV) antitumor complexes. In Howell, S. B. (Ed.), Platinum and Other Metal Coordination Complexes in Cancer Chemotherapy. Plenum Press, New York, pp. 93–100

    Chapter  Google Scholar 

  • Gibbons, G. R., Wyrick, S. and Chaney, S. G. (1989). Rapid reduction of tetrachloro(D,L-trans)1,2-diamincyclohexaneplatinum(IV) (tetraplafin) in RPMI 1640 tissue culture medium. Cancer Res., 49, 1402–1407

    PubMed  CAS  Google Scholar 

  • Gibson, D., Gean, K.-F., Ben-Shoshan, R., Ramu, A., Ringel, I. and Katzhendler, J. (1991). Preparation, characterization, and anticancer activity of a series of cis-PtC12 complexes linked to anthraquinone intercalators. J. Med. Chem., 34, 414–420

    Article  PubMed  CAS  Google Scholar 

  • Gietema, J. A., de Vries, E. G. E., Sleijfer, D. Th., Aulenbacher, P., Williemse, P. H. B. and Mulder, N. H. (1992). Clinical studies with 1,2-diamminomethylcyclobutane-platinum(II)-lactate (D19466; Lobaplatin). Ann. Oncol., 3 (Suppl. 1), A337

    Google Scholar 

  • Goddard, P. M., Valenti, M. R. and Harrap, K. R. (1991). The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: A cautionary note. Ann. Oncol., 2, 535–540

    PubMed  CAS  Google Scholar 

  • Gore, M., Fryatt, I., Wiltshaw, E., Dawson, T., Robinson, B. and Calvert, A. (1989). Cisplatin/carboplatin cross-resistance in ovarian cancer. Br. J. Cancer, 60, 767–769

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Grunicke, H. H., Hofmann, J., Maly, K., Oberhuber, H., Uberall, F., Egle, A. and Demuth, L. (1991). Enhancement of the antiproliferative effect of cisdiamminedichloro platinum (II) and other antitumor agents by inhibitors of enzymes involved in growth factor signal-transduction. In Howell, S. B. (Ed.), Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Plenum Press, New York, pp. 161–172

    Chapter  Google Scholar 

  • Hamers, F. P. T., Gerritsen van der Hoop, R., Steerenberg, P. A., Neijt, J. P. and Gispen, W. H. (1991). Putative neurotrophic factors in the protection of cisplatin-induced peripheral neuropathy in rats. Toxicol. Appl. Pharmacol., 111, 514–522

    Google Scholar 

  • Harrap, K. R. (1983). Platinum analogues: criteria for selection. In Muggia, F. M. (Ed.), Cancer Chemotherapy 1. Martinus Nijhoff, The Hague, pp. 171–217

    Chapter  Google Scholar 

  • Harrap, K. R., Jones, M., Siracky, J., Pollard, L. and Kelland, L. R. (1990). The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs. Ann. Oncol., 1, 65–76

    PubMed  CAS  Google Scholar 

  • Hanap, K. R., Kelland, L. R., Jones, M., Goddard, P. M., On, R. M., Morgan, S. E., Murrer, B. A., Abrams, M. J. and Giandomenico, C. M. (1991a). Platinum coordination complexes which circumvent cisplatin resistance. Adv. Enzyme Regulation, 31, 31–43

    Article  Google Scholar 

  • Hanap, K. R., Murrer, B. A., Giandomenico, C., Morgan, S. E., Kelland, L. R., Jones, M., Goddard, P. M. and Schurig, J. (1991b). Ammine/amine platinum IV dicarboxylates: a novel class of complexes which circumvent intrinsic cisplatin resistance. In Howell, S. B. (Ed.), Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Plenum Press, New York, pp. 391–399

    Google Scholar 

  • Hecquet, B., Fournier, C., Boughattas, N. and Levi, F. (1992). Pharmacokinetics and tissue distribution of IOHP in mice with comparison to cisplatin and carboplatin. Ann. Oncol., 3 (Suppl. 1), A530

    Google Scholar 

  • Hill, B. T., Shellard, S. A., Whelan, R. D. H., Pera, M. F., Harstrick, A. and Fichtinger-Schepman, A. M. J. (1992). Deficient removal of the major platinum-DNA intrastrand crosslinks in the sequences pGpG and pApG appears characteristic of testicular teratoma cell lines derived from tumours from untreated patients and may account for their sensitivity to cisplatin. Proc. Am. Soc. Clin. Oncol., 11, A221

    Google Scholar 

  • Hills, C. A., Kelland, L. R., Abel, G., Siracky, J., Wilson, A. P. and Harrap, K. R. (1989). Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br. J. Cancer, 59, 527–534

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Hofmann, J., Doppler, W., Jakob, A., Maly, K., Posch, L., Uberall, F. and Grunicke, H. H. (1988). Enhancement of the antiproliferative effect of cisdiamminedichloroplatinum (II) and nitrogen mustard by inhibitors of protein kinase C. Int. J. Cancer, 42, 382–388

    Article  PubMed  CAS  Google Scholar 

  • Hofmann, J., Ueberall, F., Posch, L., Maly, K., Herrmann, D. B. J. and Grunicke, H. (1989). Synergistic enhancement of the antiproliferative activity of cis-diamminedichloro platinum(II) by the ether lipid analogue BM41440, an inhibitor of protein kinase C. Lipids, 24, 312–317

    Article  PubMed  CAS  Google Scholar 

  • Hollis, S. L., Amundsen, A. R. and Stern, E. W. (1989). Chemical and biological properties of a new series of cis-diammineplatinum(II) antitumor agents containing three nitrogen donors: cis-[Pt(NH3)2(N-donor)Cl]. J. Med. Chem., 32, 128–136

    Article  PubMed  CAS  Google Scholar 

  • Hollis, S. L., Sundquist, W. I., Burstyn, J. N., Heiger-Bernays, W. J., Bellon, S. F., Ahmed, K. J., Amundsen, A. R., Stern, E. W. and Lippard, S. J. (1991). Mechanistic studies of a novel class of trisubstituted platinum(II) antitumor agents. Cancer Res., 51, 1866–1875

    PubMed  CAS  Google Scholar 

  • Hosking, L. K., Whelan, D. H., Shellard, S. A., Bedford, P. and Hill, B. T. (1990). An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumour agents shown by a range of human tumour cell lines. Biochem. Pharmacol., 40, 1833–1842

    Article  PubMed  CAS  Google Scholar 

  • Hospers, G. A. P., Mulder, N. H., de Jong, B., de Ley, L., Uges, D. R. A., Fichtinger-Schepman, A. M. J., Scheper, R. J. and de Vries, E. G. E. (1988). Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloro platinum (II) in vitro. Cancer Res., 48, 6803–6807

    PubMed  CAS  Google Scholar 

  • Howell, S. B., Isonishi, S., Christen, R. C., Andrews, P. A., Mann, S. C. and Horn, D. (1991). Signal transduction pathway regulation of DDP sensitivity. In Howell, S. B. (Ed.), Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Plenum Press, New York, pp. 173–179

    Chapter  Google Scholar 

  • Hudes, G. R., O’Dwyer, P. J., Walczak, J., LaCreta, F. P., Cohen, I., Kowal, C., Boyd, R. A. and Whitfield, L. R. (1991). Phase I/pharmacokinetic study of the new platinum compound CI-973 on a 5-day schedule. Proc. Am. Assoc. Cancer Res., 32, A1190

    Google Scholar 

  • Hydes, P. C. and Russell, M. J. H. (1988). Advances in platinum cancer chemotherapy: Advances in the design of cisplatin analogues. Cancer and Metastasis Reviews, 7, 67–89

    Article  PubMed  CAS  Google Scholar 

  • Isonishi, S., Andrews, P. A. and Howell, S. B. (1990). Increased sensitivity to cis-diamminedichloro platinum (II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. J. Biol. Chem., 265, 3623–3627

    PubMed  CAS  Google Scholar 

  • Isonishi, S., Hom, D. K., Thiebaut, F. B., Mann, S. C., Andrews, P. A., Basu, A., Lazo, J. S., Eastman, A. and Howell, S. B. (1991). Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. Cancer Res., 51, 5903–5909

    PubMed  CAS  Google Scholar 

  • Jiao, L., Funato, T., Wang, W., Tone, T., Kashani-Sabet, M. and Scanlon, K. J. (1991). The role of the c-fos oncogene in cisplatin resistance. In Howell, S. B. (Ed.), Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Plenum Press, New York, pp. 303–313

    Chapter  Google Scholar 

  • Jones, A. L., McKeage, M., Davies, C., Holburn, J., Ashley, S. E., Rastogi, R., Townsend, H. and Smith, I. E. (1992a). Phase II study of zeniplatin in advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. (in press)

    Google Scholar 

  • Jones, J. C., Zhen, W., Reed, E., Parker, R. J., Sancar, A. and Bohr, V. A. (1991). Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand crosslinks in Chinese hamster ovary cells. J. Biol. Chem., 266, 7101–7107

    PubMed  CAS  Google Scholar 

  • Jones, M., Siracky, J., Kelland, L. R. and Hanap, K. R. (1992b). Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts. Br. J. Cancer, 67, 27–29

    Google Scholar 

  • Kameyama, Y., Okazaki, N., Nakagawa, M., Koshida, H., Nakamura M. and Gemba, M. (1990). Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney slices. Toxicol. Len., 52, 15–24

    Article  CAS  Google Scholar 

  • Kanzawa, F., Matsushima, Y., Nakagawa, K., Takahashi, H., Sasaki, Y. and Saijo, N. (1988) Antitumour activity of a new platinum compound (glycolate-) diammineplatinum (II) (254-S), against non-small cell lung carcinoma grown in a human tumour clonigenic assay system. Anticancer Res., 8, 323–328

    PubMed  CAS  Google Scholar 

  • Kasahara, K., Fujiwara, Y., Nishio, K., Ohmori, T., Sugimoto, Y., Komiya, K., Matsuda, T. and Saijo, N. (1991). Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res., 51, 3237–3242

    PubMed  CAS  Google Scholar 

  • Kashani-Sabet, M., Wang, W. and Scanlon, K. J. (1990). Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. J. Biol. Chem., 265, 11285–11288

    PubMed  CAS  Google Scholar 

  • Kawai, K., Kamatani, N., Georges, E. and Ling, V. (1990). Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cis-diamminedichloro platinum (II). J. Biol. Chem., 265, 13137–13142

    PubMed  CAS  Google Scholar 

  • Kawai, K., Kamatani, N., Kuroshima, S., Nobori, T., Nishioka, K., Kamiya, H., Sakurai, M. and Mikanagi, K. (1987). Cross-resistance to ouabain in a murine leukemia cell variant selected for cis-diammine dichloro platinum(II) resistance. Cancer Lett., 35, 147–152

    Article  PubMed  CAS  Google Scholar 

  • Kelland, L. R., Jones, M., Abel, G. and Harrap, K. R. (1992a). Human ovarian carcinoma cell lines and companion xenografts: a disease oriented approach to new platinum anticancer drug development. Cancer Chemother. Pharmacol., 30, 43–50

    Article  PubMed  CAS  Google Scholar 

  • Kelland, L. R., Jones, M., Goddard, P. M., Murrer, B. A. and Hanap, K. R. (1992b). Preclinical antitumor activity of Bis-acetato-ammine dichloro (cyclohexylamine) platinum (IV) (JM216): An orally active platinum drug. Proc. Am. Assoc. Cancer Res., 33, A3342

    Google Scholar 

  • Kelland, L. R., Mistry, P., Abel, G., Freidlos, F., Loh, S. Y., Roberts, J. J. and Harrap, K. R. (1992c). Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular non-seminomatous germ cell line. Cancer Res., 52, 1710–1716

    PubMed  CAS  Google Scholar 

  • Kelland, L. R., Mistry, P., Abel, G., Loh, S. Y., O’Neill, C. F., Murrer, B. A. and Hanap, K. R. (1992d). Mechanism-related circumvention of cis-diamminedichloro platinum (II) acquired resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum (IV) dicarboxylates. Cancer Res., 52, 3857–3864

    PubMed  CAS  Google Scholar 

  • Kelland, L. R., Murrer, B. A., Abel, G., Giandomenico, C. M., Mistry, P. and Hanap, K. R. (1992e). Ammine/amine platinum (N) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian cell lines. Cancer Res., 52, 822–828

    PubMed  CAS  Google Scholar 

  • Kelland, L. R., Murrer, B. A., Abel, G. and Hanap, K. R. (1991). Structure-activity relationships in a series of novel platinum (II) and platinum (IV) ammine/amine complexes evaluated against a panel of human ovarian carcinoma cell lines. J. Cell Pharmacol., 2, 331–342

    Google Scholar 

  • Kelley, S. L., Basu, A., Teicher, B. A., Hacker, M. P., Hamer, D. H. and Lazo, J. S. (1988). Overexpression of metallothionein confers resistance to anticancer drugs. Science, 241, 1813–1815

    Article  PubMed  CAS  Google Scholar 

  • Kelley, S. L. and Rozencweig, M. (1989). Resistance to platinum compounds: mechanisms and beyond. Eur. J. Cancer Clin. Oncol., 25, 1135–1140

    Article  PubMed  CAS  Google Scholar 

  • Kelsen, D. P., Scher, H., Burchenal, J. (1984). In Hacker, M. P., Douple, E. B. and Krakoff, I. H. (Eds), Platinum Coordination Complexes in Cancer Chemotherapy. Martinus Nijhoff, Boston, pp. 311–320

    Google Scholar 

  • Kerr, D. J., Khan, M., Plumb, J. A., Freshney, R. I. and Spandidos, D. A. (1991). The effect of H-ras and c-myc oncogene transfection on the response of epithelial cells to cisplatin and growth factors. Proceedings of the Sixth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, p. 96

    Google Scholar 

  • Khokhar, A. R., Al-Baker, S., Krakoff, I. H. and Perez-Soler, R. (1989). Toxicity and antitumour activity of cis-bis-carboxylato(trans-R,R-1,2-diaminocyclohexane) platinum(II) complexes entrapped in liposomes. Cancer Chemother. Pharmacol., 23, 219–224

    Article  PubMed  CAS  Google Scholar 

  • Khokhar, A. R., Al-Baker, S., Krakoff, I. H. and Perez-Soler, R. (1992). Chemical and biological properties of highly lipophilic cisplatin analogues entrapped in liposomes. Proc. Am. Assoc. Cancer Res., 33, A3227

    Google Scholar 

  • Kidani, Y., Inagaki, K., Iigo, M., Hoshi, A. and Kazuo, K. (1978). Antitumour activity of 1,2-diaminocyclohexane-platinum complexes against sarcoma-180 ascites form. J. Med. Chem., 21 (12), 1315–1318

    Article  PubMed  CAS  Google Scholar 

  • Kikuchi, Y., Iwano, I., Miyauchi, M., Kita, T., Sugita, M., Tenjin, Y. and Nagata, (1990a). Possible mechanisms of resistance to cis-diamminedichloroplatinum (II) of human ovarian cancer cells. Jpn J. Cancer Res., 81, 701–706

    Article  PubMed  CAS  Google Scholar 

  • Kikuchi, Y., Iwano, I., Miyauchi, M., Sasa, H., Nagata, I. and Kuki, E. (1990b). Restorative effects of calmodulin antagonists on reduced cisplatin uptake by cisplatin-resistant human ovarian cancer cells. Gynecol. Oncol., 39, 199–203

    Article  PubMed  CAS  Google Scholar 

  • Kimura, E., Enns, R. E., Arboleda, M. J., Slamon, D. J. and Howell, S. B. (1992). Correlation of survival with mRNA expression of 60 kD heat shock protein (HSP-60) in ovarian cancer patients. Proc. Am. Soc. Clin. Oncol., 11, A225

    Google Scholar 

  • Knebel, N. G. and Von Angerer, E. (1991). 2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum (II): complexes with a selective action on estrogen receptor positive mammary tumors. J. Med. Chem., 34, 2145–2152

    Google Scholar 

  • Knox, R. J., Friedlos, F., Lydall, D. A. and Roberts, J. J. (1986). Mechanism of cytotoxicity of anticancer platinum drugs: Evidence that cis-diamminedichloro platinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res., 46, 1972–1979

    PubMed  CAS  Google Scholar 

  • Kraker, A. J. and Moore, C. W. (1988a). Accumulation of cis-diamminedichloro platinum (II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Res., 48, 9–13

    PubMed  CAS  Google Scholar 

  • Kraker, A. J. and Moore, C. W. (1988b). Elevated DNA polymerase beta activity in a cis-diamminedichloro platinum (II) resistant P388 murine leukemia cell line. Cancer Lett., 38, 307–314

    Article  PubMed  CAS  Google Scholar 

  • Kramer, B. S., Birch, R., Greco, A., Prestridge, K., DeSimone, P. and Omura, G. (1988). Randomized phase II evaluation of iproplatin (CHIP) and carboplatin (CBDCA) in lung cancer. Am. J. Clin. Oncol., 11, 643 645

    Google Scholar 

  • Kreisman, H., Ginsberg, S., Propert, K. J., Richards, F., Graziano, S. and Green, M. (1987). Carboplatin or iproplatin in advanced non-small cell lung cancer: A Cancer and Leukaemia Group B study. Cancer Treat. Rep., 71, 1049–1052

    PubMed  CAS  Google Scholar 

  • Kuppen, P. J. K., Schuitemaker, H., Veer, L. J., Bruijn, E. A., Oosterom, A. T. and Schrier, P. I. (1988). cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Res., 48, 3355–3359

    Google Scholar 

  • Lai, G. M., Ozols, R. F., Smyth, J. F., Young, R. C. and Hamilton, T. C. (1988). Enhanced DNA repair to cisplatin in human ovarian cancer. Biochem. Pharma-col., 37, 4597–4600

    Article  CAS  Google Scholar 

  • Lai, G. M., Ozols, R. F., Young, R. C. and Hamilton, T. C. (1989). Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. Natl Cancer Inst., 81, 535–539

    Article  CAS  Google Scholar 

  • Lévi, F., Misset, J-L., Brienza, S., Adam, R., Metzger, G., Itzakhi, M., Caussanel, J-P., Kunstlinger, F., Lecouturier, S., Descorps-Declére, A., Jasmin, C., Bismuth, H. and Reinberg, A. (1992). A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. Cancer, 69, 893–900

    Article  PubMed  Google Scholar 

  • Lewis, A. D., Hayes, J. D. and Wolf, C. R. (1988). Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects. Carcinogenesis, 9, 1283–1287

    Article  PubMed  CAS  Google Scholar 

  • Loh, S. Y., Mistry, P., Kelland, L. R., Abel, G., and Harrap, K. R. (1992). Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br. J. Cancer, 66, 1109–1115

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Los, G., Mutsaers, P. H., Ruevekamp, M., McVie, J. G. (1990). The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat. Cancer Lett., 51, 109–117

    Article  PubMed  CAS  Google Scholar 

  • McGuire III, W. P., Arseneau, J., Blessing, J. A., DiSaia, P. J., Hatch. K. D., Given, F. T., Teng, N. N. H. and Creasman, W. T. (1989). A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: A Gynecology Oncology Group study. J. Clin. Oncol., 7, 1462–1468

    Google Scholar 

  • McKeage, M. J., Morgan, S. E., Boxall, F. E., Hard, G. C., Murrer, B., Judson, I. and Harrap, K. (1992). Acute toxicology of orally administered bis-acetatoammine dichloro (cyclohexylamine) platinum(IV) (JM216) in rodents. Proc. Am. Assoc. Cancer Res., 33, A3197

    Google Scholar 

  • Majima, H. (1991). Clinical studies with cisplatin analogues, 254-S, DWA 2114R and NK121. In Howell, S. B. (Ed.), Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Plenum Press, New York, pp. 345–355

    Chapter  Google Scholar 

  • Mangioni, C., Bolis, G., Pecorelli, S., Bragman, K., Epis, A., Favalli, G., Gambino, A., Landoni, F., Presti, M., Tom, W., Vassena, L., Zanaboni, F. and Marsoni, S. (1989). Randomised trial in ovarian cancer comparing cisplatin and carboplatin. J. Natl Cancer Inst., 81, 1464–1468

    Article  PubMed  CAS  Google Scholar 

  • Mann, S. C., Aniirews, P. A. and Howell, S. B. (1991). Modulation of cisdiamminedichloro platinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int. J. Cancer, 48, 866–872

    Article  PubMed  CAS  Google Scholar 

  • Masuda, H., Ozols, R. F., Lai, G-M., Fojo, A., Rothenberg, M. and Hamilton, T. C. (1988). Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines. Cancer Res., 48, 5713–5716

    PubMed  CAS  Google Scholar 

  • Masuda, H., Tanaka, T., Matsuda, H. and Kusaba, I. (1990). Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cisdiamminedichloroplatinum (II). Cancer Res., 50, 1863–1866

    PubMed  CAS  Google Scholar 

  • Mathé, G., Kidani, Y., Noji, M., Maral, R., Bourut, C. and Chenu, E. (1985). Antitumor activity of 1-OHP in mice. Cancer Lett., 27, 135–143

    Article  PubMed  Google Scholar 

  • Mathé, G., Kidani, Y., Segiguchi, M., Eriguchi, M., Fredj, G., Peytavin, G., Misset, J. L., Brienza, S., De Vassals, F., Chenu, E. and Bourut, C. (1989). Oxalato-platinum or 1-OHP, a third-generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed. Pharmacother., 43, 237–250

    Article  PubMed  Google Scholar 

  • Mathé, G., Kidani, Y., Triana, K., Brienza, S., Ribaud, P., Goldschmidt, E., Ecstein, E., Despax, R., Musset, M. and Misset, J. L. (1986). A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (1-OHP). Biomed. Pharmacother., 40, 372–376

    PubMed  Google Scholar 

  • Matsumoto, T., Endoh, K., Akamatsu, K., Kamisango, K., Mitsui, H., Koizumi, K., Morikawa, K., Koizumi, M. and Matsuno, T. (1991). Comparison of the anti-tumour effects and nephrotoxicity-inducing activities of two new platinum complexes (—)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum(II) monohydrate, and its enantiomeric isomer. Br. J. Cancer, 64, 41–46

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Meijer, C., Mulder, N. H., Timmer-Bosscha, H., Meersma, G. J. and De-Vries, E. G. (1991). Role of GSH in the efficacy of 7 platinum (Pt) compounds in 2 cisplatin (CDDP)-resistant human cell lines. Proc. Am. Assoc. Cancer Res., 32, A2427

    Google Scholar 

  • Mistry, P. and Harrap, K. R. (1991). Historical aspects of glutathione and cancer chemotherapy. Pharmacol. Ther., 49, 125–132

    Article  PubMed  Google Scholar 

  • Mistry, P., Kelland, L. R., Abel, G., Sidhar, S. and Hanap, K. R. (1991). The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br. J. Cancer, 64, 215–220

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Mistry, P., Kelland, L. R., Loh, S. Y., Abel, G., Murrer, B. A. and Harrap, K. R. (1992). Cellular accumulation and cytotoxicity of platinum drugs in five human ovarian carcinoma cell lines. Cancer Res., 52, 6188–6193

    PubMed  CAS  Google Scholar 

  • Morikage, T., Bungo, M., Inomata, M., Yoshida, M., Ohmori, T., Fujiwara, Y., Nishio, K. and Saijo, N. (1991). Reversal of cisplatin resistance with amphotericin B in a non-small cell lung cancer cell line. Jpn J. Cancer Res., 82, 747–751

    Article  PubMed  CAS  Google Scholar 

  • Muggia, F. M., Wolpert-DeFilippes, M. K., Ribaud, P. and Mathé, G. (1980). Clinical results with cisplatin analogs. In Prestayko, A. W., Crooke, S. T. and Carter, S. K. (Eds), Cisplatin: Current Status and New Developments. Academic Press, New York, pp. 517–527

    Chapter  Google Scholar 

  • Murphy, D., McGown, A. T., Crowther, D., Mander, A. and Fox, B. W. (1991). Metallothionein levels in ovarian tumours before and after chemotherapy. Br. J. Cancer, 63, 711–714

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Nakagawa, K., Yokota, J., Wada, M., Sasaki, Y., Fujiwara, Y., Sakai, M., Muramatsu, M., Terasaki, T., Tsunokawa, Y., Terada, M. and Saijo, N. (1988). Levels of glutathione S transferase IImRNA in human lung cancer cell lines correlate with the resistance to cisplatin and carboplatin. Jpn J. Cancer Res. (Gann), 79, 301–304

    Article  CAS  Google Scholar 

  • Nicholson, M. C., On, R. M., O’Neill, C. F. and Hanap, K. R. (1992). The role of platinum uptake and glutathione levels in L1210 cells sensitive and resistant to cisplatin, tetraplatin or carboplatin. Neoplasma, 39 (3), 189–195

    Google Scholar 

  • Niimi, S, Nakagawa, K., Yokota, J., Tsunokawa, Y., Nishio, K., Terashima, Y., Shibuya, M., Terada, M. and Saijo, N. (1991). Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. Br. J. Cancer, 63, 237–241

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Nishizuka, Y. (1988). The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature, 334, 661–665

    Article  PubMed  CAS  Google Scholar 

  • Olver, I., Green, M., Peters, W., Zimet, A., Toner, G., Bishop, J., Ketelbey, W., Astogi, R. and Birkhofer, M. (1992). A pilot phase II study of zeniplatin in metastatic melanoma. Ann. Oncol., 3 (Suppl. 1), A345

    Google Scholar 

  • O’Neill, C. F., Orr, R. M., Kelland, L. R. and Hanap, K. R. (1992). Formation and removal of platinum/DNA adducts in human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Proc. Am. Assoc. Cancer Res., 33, A3196

    Google Scholar 

  • O’Rourke, T., Rodriguez, G., Eckardt, J., Kuhn, J., Bums, H., Hardy, J., Weiss, G. and Von Hoff, D. (1992). Phase I clinical trial ormaplatin (NSC363812) given on a daily ×5, every 28 day schedule. Proc. Am. Assoc. Cancer Res., 33, A3215

    Google Scholar 

  • Orr, R. M., Barnard, C. F. J., Murrer, B. A., O’Neill, C. F., Nicolson, M. C., Balazova, E. and Harrap, K. R. (1992). Evaluation of novel platinum (II) and platinum (IV) ammine/amine complexes in L1210 murine leukaemia cell lines sensitive and resistant to cisplatin and tetraplatin. J. Cell Pharmacol. (in press)

    Google Scholar 

  • Ota, K., Miyake, H., Inuyama, I., Niitani, H., Kimura, I., Ogawa, M., Yoshida, M., Taguchi, T., Wakui, A., Yoshida, O., Kato, T., Noda, K., Aso, Y., Taguchi, Y. and Sakuma, A. (1992). Clinical evaluation of cis-diammine(glycolato)platinum(II), 254-S. A new anticancer platinum complex. Ann. Oncol., 3 (Suppl. 1), A340

    Google Scholar 

  • Ozols, R. F. (1991). Ovarian cancer: new clinical approaches. Cancer Treat. Rev., 18 ( Suppl. A), 77–83

    Google Scholar 

  • Parker, R. J., Eastman, A., Bostick-Bruton, F. and Reed, E. (1991). Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Invest., 87, 772–777

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Pendyala, L., Creaven, P. J., Shah, G., Molnar, M. V. and Grandjean, E. M. D. (1991). In vitro cytotoxicity studies of oxaliplatin in human tumor cell lines. Proc. Am. Assoc. Cancer Res., 32, A2441

    Google Scholar 

  • Pera, M. F., Friedlos, F., Mills, J. and Roberts, J. J. (1987). Inherent sensitivity of cultured human embryonal carcinoma cells to adducts of cis-diamminedichloro platinum (II) on DNA. Cancer Res., 47, 6810–6813

    PubMed  CAS  Google Scholar 

  • Perez-Soler, R., Khokhar, A. R. and Lopez-Berestein, G. (1987). Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) encapsulated in multilamellar vesicles. Cancer Res., 47, 6462–6466

    PubMed  CAS  Google Scholar 

  • Perez-Soler, R., Lautersztain, J., Stephens, L. C., Wright, K. and Khokhar, A. R. (1989). Preclinical toxicity and pharmacology of liposome-entrapped cisbisneodecanoato-trans-R,R-1,2-diaminocyclohexane Platinum (II). Cancer Che-mother. Pharmacol., 24, 1–8

    CAS  Google Scholar 

  • Perez-Soler, R., Lopez-Berestein, G., Lautersztain, J., Al-Baker, S., Francis, K., Macias-Kiger, D., Raber, M. N. and Khokhar, A. R. (1990). Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R1,2-diaminocyclohexane platinum (II). Cancer Res., 50, 4254–4259

    PubMed  CAS  Google Scholar 

  • Perez-Soler, R., Siddik, Z. H., Vadiei, K., Krakoff, I. H. and Khokhar, A. R. (1991). Pharmacologic studies with new liposome-entrapped cisplatin derivatives. In Howell, S. B. (Ed.), Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Plenum Press, New York, pp. 377–389

    Chapter  Google Scholar 

  • Piccart, M., Kerger, J., Tueni, E., van der Schueren, E., Kennes, C., Bartholomeus, S., Vantongelen, K., Rastogi, R. and Birkhofer, M. (1991). Phase II trial of zeniplatin (CL 286,558; ZNP) as second-line treatment in metastatic breast cancer (MBC). Proc. Am. Assoc. Cancer Res., 32, Al222

    Google Scholar 

  • Rhodes, T. and Twentyman, P. R. (1992). A study of ethacrynic acid as a potential modifier of melphalan and cisplatin sensitivity in human lung cancer parental and drug resistant cell lines. Br. J. Cancer, 65, 684–690

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Roberts, J. D., Van Houten, B., Qu, Y. and Farrell, N. P. (1989). Interaction of novel bis(platinum) complexes with DNA. Nucleic Acids Res., 17, 9719–9733

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Roberts, J. J., Knox, R. J., Friedlos, F. and Lydall, D. A. (1986). DNA as the target for the cytotoxic and anti-tumour action of platinum co-ordination complexes: comparative in vitro and in vivo studies of cisplatin and carboplatin. In McBrien, D. C. H. and Slater, T. F. (Eds), Biochemical Mechanisms of Platinum Antitumour Drugs. IRL Press, Oxford, pp. 29–64

    Google Scholar 

  • Rosenberg, B. (1985). Fundamental studies with cisplatin. Cancer, 55, 2303–2316

    Article  PubMed  CAS  Google Scholar 

  • Rubin, E., Kharbanda, S., Gunji, H., Weichselbaum, R. and Kufe, D. (1992). cis-Diamminedichloro platinum (II) induces c-jun expression in human myeloid leukemia cells: potential involvement of a protein kinase C-dependent signaling pathway. Cancer Res., 52, 878–882

    Google Scholar 

  • Saburi, Y., Nakagawa, M., Ono, M., Sakai, M., Muramatsu, M., Kohno, K. and Kuwano, M. (1989). Increased expression of glutathione S-transferase gene in cis-diamminedichloro platinum(II)-resistant variants of a Chinese hamster ovary cell line. Cancer Res., 49, 7020–7025

    PubMed  CAS  Google Scholar 

  • Sasaki, Y., Amano, T., Morita, M., Shinkai, T, Eguchi, K., Tamura, T., Ohe, Y., Kojima, A. and Saijo, N. (1991). Phase I study and pharmacological analysis of cis-diammine(glycolato) platinum(II) (254-S; NSC 375101d) administered by 5-day continuous intravenous infusion. Cancer Res., 51, 1472–1477

    PubMed  CAS  Google Scholar 

  • Sasaki, Y., Tamura, T., Eguchi, K., Shinkai, T., Fujiwara, Y., Fukuda, M., Ohe, Y., Bungo, M., Horichi, N., Niimi, S., Minato, K., Nakagawa, K. and Saijo, N. (1989). Pharmacokinetics of [glycolato-O,O’]-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Che-mother. Pharmacol., 23, 243–246

    Article  CAS  Google Scholar 

  • Scanlon, K. J., Jiao, L., Funato, T., Wang, W., Tone, T., Rossi, J. J. and Kashani-Sabet, M. (1991). Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc. Natl Acad. Sci. USA, 88, 10591–10595

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Scanlon, K. J., Kashani-Sabet, M., Miyachi, H., Sowers, L. and Rossi, J. (1989a). Molecular basis of cisplatin resistance in human carcinomas: Model systems and patients. Anticancer Res., 9, 1301–1312

    PubMed  CAS  Google Scholar 

  • Scanlon, K. J., Kashani-Sabet, M. and Sowers, L. C. (1989b). Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine. Cancer Commun., 1, 269–275

    PubMed  CAS  Google Scholar 

  • Schilder, R. J., Hall, L., Monks, A., Handel, L. M., Fornace, Jr A. J., Ozols, R. F., Fojo, A. T. and Hamilton, T. C. (1990). Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int. J. Cancer, 45, 416–422

    Article  PubMed  CAS  Google Scholar 

  • Schilder, R. J., LaCreta, F. P., Perez, R. P., Nash, S., Hamilton, T. C., Goldstein, L. J., Young, R. C., Ozols, R. F. and O’Dwyer, P. J. (1992). Phase U pharmacokinetic study of ormaplatin (tetraplatin, NSC363812). Proc. Am. Assoc. Cancer Res., 33, A3211

    Google Scholar 

  • Sekiguchi, M., Eriguchi, M., Shiroko, Y., Akiyama, N. and Mikamo, S. (1992). Chemosensitivity screening in vitro of various cultured human cancer cell lines to a new platinum complex. l-OHP: Oxalato(trans-l-1,2-diaminocyclohexane)platinum(II). Ann. Oncol., 3 (Suppl. 1), A194

    Google Scholar 

  • Shiratori, O., Kasi, H., Uchida, N., Takeda, Y., Totano, T. and Sato, K. (1985). Antitumour activity of 254-S, a platinum complex, in rodents. In Shigama, J. (Ed.), Recent Advances in Chemotherapy: Anticancer Section 1. University of Tokyo Press, Tokyo, pp. 635–636

    Google Scholar 

  • Silvestro, L., Anal, H., Sommer, F., Trincal, G. and Tapiero, H. (1990). Comparative effects of a new platinum analog (trans-l-diamine-cyclohexane oxalatoplatinum: l’OHP) with CDDP on various cells: correlation with intracellular accumulation. Anticancer Res., 10 (5B), 1376

    Google Scholar 

  • Sklar, M. D. (1988). Increased resistance to cis-diamminedichloro platinum (II) in NIH 3T3 cells transformed by ras oncogenes. Cancer Res., 48, 793–797

    PubMed  CAS  Google Scholar 

  • Sklar, M. D. and Prochownik, E. V. (1991). Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc. Cancer Res., 51, 2118–2123

    PubMed  CAS  Google Scholar 

  • Tamura, K., Makino, S. and Araki, Y. (1990). A phase I study of a new cisplatin derivative for haematological malignancies. Cancer, 66, 2059–2063

    Article  PubMed  CAS  Google Scholar 

  • Tashiro, T., Kawada, Y., Sakurai, Y. and Kidani, Y. (1989). Antitumour activity of a new platinum complex oxalato [trans-1,2-diaminocyclohexane platinum(II): new experimental data. Biomed. Pharmacother., 43, 251–260

    Article  PubMed  CAS  Google Scholar 

  • Teicher, B. A., Herman, T. S., Holden, S. A., Wang, Y. M., Peeffer, R., Crawford, J. W. and Frei, E. III (1990a). Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science, 245, 1457–1461

    Google Scholar 

  • Teicher, B. A., Holden, S. A., Herman, T. S., Sotomayor, E. A., Khandekar, V., Rosbe, K. W., Brann, T. W., Korbut, T. T. and Frei, E. III (1990b). Characteristics of five human tumor cell lines and sublines resistant to cisdiamminedichloro platinum (II). Int. J. Cancer, 47, 252–260

    Article  Google Scholar 

  • Teicher, B. A., Holden, S. A., Kelley, M. J., Shea, T. C., Cucchi, C. A., Rosowsky, A., Henner, W. D. and Frei, E. III (1987). Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloro platinum (II). Cancer Res., 47, 388–393

    PubMed  CAS  Google Scholar 

  • Theriault, R., Esparza, L., Raber, M., Newman, R., Krakoff, I., Cohen, I. and Kowal, C. (1990). Phase I evaluation of [SP-4–3-(R)]-[1,1-cyclobutane-dicarboxylato(2-)](2-methyl-1,4-butanediamine-N,N’)platinum(CI-973). Proc. Am. Assoc. Cancer Res., 31, A1170

    Google Scholar 

  • Toffoli, G., Viel, A., Tumiotto, L., Buttazzi, P., Biscontin, G. and Boiocchi, M. (1989). Sensitivity pattern of normal and Ha-ras transformed NIH3T3 fibroblasts to antineoplastic drugs. Tumori, 75, 423–428

    PubMed  CAS  Google Scholar 

  • Trask, C., Silverstone, A., Ash, C. M., Earl, H., Irwin, C., Bakker, A., Tobias, J. S. and Souhami, R. L. (1991). A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer. J. Clin. Oncol., 9, 1131–1137

    PubMed  CAS  Google Scholar 

  • Trump, D. L., Petros, W., Chaney, S., Smith, D. C., Fangmeier, J., Brown, T. D. and Goldberg, H. (1992). Phase I clinical trial and study of the pharmacokinetics and metabolism of ormaplatin (tetraplatin, NSC363812). Proc. Am. Assoc. Cancer Res., 33, A3217

    Google Scholar 

  • Tutsch, K. D., Arzoomanian, R. Z., Alberti, D., Feierabend, C., Robins, H. I. and Spriggs, D. R. (1992). Phase I and pharmacokinetic study of ormaplatin. Proc. Am. Assoc. Cancer Res., 33, A3202

    Google Scholar 

  • Van Beusichem, M. and Farrell, N. (1992). Activation of the trans geometry in platinum antitumor complexes. Synthesis, characterization, and biological activity of complexes with the planar ligands pyridine, N-methylimidazole, thiazole, and quinoline. Crystal and molecular structure of trans-dichlorobis (thiazole)platinum(II). Inorg. Chem., 31, 634–639

    Article  Google Scholar 

  • Vermorken, J. B., ten Bokkel Huinink, W. W., McVie, J. G., van der Vijgh, W. J. F. and Pinedo, H. M. (1984). Clinical experience with 1,1-diaminocyclohexane(sulphate) platinum(II)(TNO6). In Hacker, M. P., Douple, E. B. and Krakoff, I. H. (Eds), Platinum Coordination Complexes in Cancer Chemotherapy. Martinus Nijhoff, Boston, pp. 330–343

    Chapter  Google Scholar 

  • Von Angerer, E., Bimbock, H. and Knebel, N. (1989). Platinum complexes with a selective action on estrogen receptor-positive mammary tumors. Anti-cancer Drug Design, 4, 21–35

    Google Scholar 

  • Wagstaff, A. J., Ward, A., Benfield, P. and Heel, R. C. (1989). Carboplatin: A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs, 37 (2), 163–186

    Article  Google Scholar 

  • Walker, M. C., Parris, C. N. and Masters, J. R. W. (1987). Differential sensitivities of human testicular and bladder tumor cell lines to chemotherapeutic drugs. J. Natl Cancer Inst.., 79, 213–216

    PubMed  CAS  Google Scholar 

  • Waud, W. R. (1987). Differential uptake of cis-diamminedichloro platinum (II) by sensitive and resistant murine leukemia cells. Cancer Res., 47, 6549–6555

    PubMed  CAS  Google Scholar 

  • Willemse, P. H., Gieterra, J. A., Sleijfer, D. T., Mulder, N. H., de Vries, E. G., de Halleux, F., Rastogi, R. B. and Birkhofer, M. (1991). Activity of a third generation platinum compound zeWiplatin (CL 286,558) in patients with recurrent ovarian cancer. Proc. Am. Soc. Clin. Oncol., 10, A626

    Google Scholar 

  • Wolf, C. R., Hayward, I. P., Lawrie, S. S., Buckton, K., McIntyre, M. A., Adams, D. J., Lewis, A. D., Scott, A. R. R. and Smyth, J. F. (1987). Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int. J. Cancer, 39, 696–702

    Article  Google Scholar 

  • Yarbo, J. W. (Ed.) (1992). Carboplatin (JM8) update: Current perspectives and future directions. Seminars in Oncology, 19(Suppl. 2), 1–164 Grune and Stratton, Philadelphia

    Google Scholar 

  • Zinkewich-Peotti, K. and Andrews, P. A. (1992). Loss of cis-diamminedichloro platinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance. Cancer Res., 52, 1902–1906

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Mark J. McKeage
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lloyd R. Kelland
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute of Cancer Research, Sutton, Surrey, UK

    Stephen Neidle

  2. Department of Pharmacology, University of Cambridge, CB2 1QJ, Cambridge, UK

    Michael J. Waring

Copyright information

© 1993 The contributors

About this chapter

Cite this chapter

McKeage, M.J., Kelland, L.R. (1993). New Platinum Drugs. In: Neidle, S., Waring, M.J. (eds) Molecular Aspects of Anticancer Drug-DNA Interactions. Topics in Molecular and Structural Biology. Palgrave, London. https://doi.org/10.1007/978-1-349-12356-8_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-349-12356-8_6

  • Publisher Name: Palgrave, London

  • Print ISBN: 978-1-349-12358-2

  • Online ISBN: 978-1-349-12356-8

  • eBook Packages: EngineeringEngineering (R0)

Publish with us

Policies and ethics

Search

Navigation